Back to News
Market Impact: 0.55

Chip Stocks Just Fell 8 Days in a Row, Their Longest Losing Streak Since 2008

Source: 247wallst.com

+1
Artificial IntelligenceTechnology & InnovationMarket Technicals & FlowsInvestor Sentiment & PositioningInterest Rates & YieldsEnergy Markets & PricesAnalyst InsightsCompany Fundamentals
Chip Stocks Just Fell 8 Days in a Row, Their Longest Losing Streak Since 2008

The Philadelphia semiconductor index fell 3.8% on October 16, extending its losing streak to eight sessions—the longest since 2008—while the Nasdaq 100 dropped 2.5% and tech stocks lost more than $1 trillion in value. SOXX fell 4.14% to $493.39, down about 16% since October 6, amid concern that high oil prices, a 5.10% 10-year Treasury yield and doubts about AI-related capital spending could pressure the chip supply chain. Bank of America analyst Sebastian Raedler said hyperscaler capex forecasts rose from $330 billion in early 2025 to $1 trillion and warned that major capital cycles have often disappointed; the article also notes the selloff may reflect repricing and position unwinding, not confirmed spending cuts.

Analysis

The key risk is not simply a weaker AI narrative: higher oil and yields can raise the discount rate just as investors question the return on hyperscaler capex. That combination can compress long-duration chip valuations even if near-term orders remain intact. If buyers defer projects, equipment suppliers may feel it before chip revenue does: fab build schedules are adjustable, so order pushouts can transmit quickly to KLA, Lam Research and Applied Materials. Memory and networking exposure could then weaken through delayed deployments, not necessarily current demand deterioration.

The cross-chain selloff is a positioning warning, not confirmation of a capex reversal. The article offers no hyperscaler guidance revisions or order data; the $1 trillion spending figure is an analyst estimate, not realized spend. Nvidia’s relative resilience may reflect perceived execution strength, but does not insulate it from a sector-wide multiple reset. AMD has additional shipment and product-execution risk, while its stated customer plans extend into 2027.

Near term, watch oil, Treasury yields and whether selling broadens or volatility rises. Over 1–3 months, hyperscaler earnings and capex commentary are the decisive catalysts. Over 6–18 months, the question is whether AI workloads generate returns sufficient to sustain infrastructure budgets. The contrarian opportunity is that prices may be discounting cuts before buyers confirm them; conversely, a rebound without capex evidence could be only positioning relief.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly negative

Sentiment Score

-0.35

Ticker Sentiment

AMAT-0.35
AMD-0.50
AVGO-0.35
INTC-0.35
KLAC-0.45
LRCX-0.45
MRVL-0.35
MU-0.35
NVDA-0.25

Key Decisions for Investors

  • Avoid adding broad semiconductor beta solely because of the losing streak. Treat hyperscaler capex guidance as the confirmation signal; the article provides no independent evidence that budgets have been cut.
  • If major hyperscalers reaffirm spending and SOXX reclaims $589.45, consider a measured long SOXX versus short AMD, sized to control beta. This captures broad-cycle recovery while limiting reliance on AMD’s Helios execution; reassess if AMD shipment timing or customer commitments improve materially.
  • If buyers indicate project delays, favor underweighting KLAC, LRCX and AMAT versus less capex-sensitive exposure: equipment orders can be deferred ahead of realized chip-demand declines. Falsify this view if equipment-company order/backlog commentary remains firm and hyperscaler budgets hold.
  • Keep gross exposure modest while oil and rates remain adverse. A further rise in crude or the 10-year yield would pressure sector multiples even absent earnings cuts; a sustained reversal in either, alongside stable capex plans, would weaken the bearish setup.

More News

From AllMind Research

Browse all research